Secukinumab

(Cosentyx®)

Secukinumab

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (subcutaneous; 300 mg/2 mL, 150 mg/mL); Pediatric injection (subcutaneous; 75 mg/0.5 mL); Injection (intravenous infusion; 125 mg/5 mL);
Drug ClassHuman interleukin-17A antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.
  • Indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.
  • Indicated for the treatment of adults with active ankylosing spondylitis (AS).
  • Indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
  • Indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Secukinumab (Cosentyx) is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial spondyloarthritis with objective signs of inflammation. It is also used in treating adults with enthesitis-related arthritis.
  • Fifty-eight systematic reviews/meta-analyses were reviewed to gather information about Secukinumab.
  • In terms of efficacy and safety, Secukinumab ranked highest in achieving clear/minimal disease activity in Palmoplantar Psoriasis compared to other treatments. For Palmoplantar Pustulosis, the data were less definitive across treatments, but Secukinumab showed promising outcomes.
  • When treating Psoriatic Arthritis, Secukinumab demonstrated superior efficacy along with infliximab and adalimumab at a 6-month follow-up period. The safety profile was consistent, suggesting it as an acceptable alternative compared to other treatments.
  • For Moderate-to-Severe Psoriasis patients, direct and indirect comparisons revealed that Secukinumab, along with interleukin inhibitors like ixekizumab, showed superior efficacy in achieving PASI 90 responses, indicating significant skin clearance potential.
  • In cases involving Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis conditions; effectiveness and safety were observed, with treatments showing improvements on ASAS20/40 response rates as well as physical function over varying trial durations, which underlines its utility for long-term management purposes.
  • Nail Psoriasis can be effectively managed using various biologics, including Secukinumab, although it did not emerge as the absolute leader based on all parameters, hence choice could be tailored according to patient needs or specific disease manifestations.
  • Secukinumab consistently displayed favorable safety profiles across different indications, often ranking among top treatments especially for achieving clear or almost clear skin in Psoriasis and treating Psoriatic Arthritis with a good balance between efficacy and safety. It also showed significant patient improvement without raising major safety concerns when managing Ankylosing Spondylitis and non-radiographic axial Spondyloarthritis.
  • While Secukinumab's overall performance across the general population afflicted with the mentioned conditions is robust, there was no thorough analysis of subgroup considerations such as age, sex, or ethnicity that allows for granular conclusions.
  • The drug has shown to be effective both in patients previously untreated with biologics and in biologic-experienced populations, suggesting it is a viable first-line treatment option and an effective alternative for those who have failed other biologic therapies.

Product Monograph / Prescribing Information

Document TitleYearSource
Cosentyx (secukinumab) Prescribing Information.2023Novartis Pharmaceuticals Corporation., East Hanover, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Small-molecule inhibitors and biologics for palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis.2024American journal of clinical dermatology
Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis.2024Advances in Rheumatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis.2023The Cochrane Database of Systematic Reviews
Efficacy and safety of nail psoriasis targeted therapies: a systematic review.2023American Journal of Clinical Dermatology
Evaluation of the synovial effects of biological and targeted synthetic dmards in patients with psoriatic arthritis: a systematic literature review and meta-analysis.2023Internation Journal of Molecular Sciences
Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis of randomized clinical trials.2023Journal of the American Academy of Dermatology
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis2023Rheumatology (Oxford)
Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis.2023Expert Review of Clinical Immunology
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.2023Annals of the Rheumatic Diseases
Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling.2023Expert review of clinical pharmacology
Efficacy and safety of secukinumab for the treatment of psoriasis: a meta-analysis of pivotal phase III trials.2023Dermatology
Comparative efficacy of biologic disease-modifying anti-rheumatic drugs for non-radiographic axial spondyloarthritis: a systematic literature review and Bucher indirect comparisons.2023Rheumatology and therapy
Clinical and economic benefit of advanced therapies for the treatment of active ankylosing spondylitis2023Rheumatology and therapy
Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.2022Journal of the German Society of Dermatology
Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: a systematic review and network meta-analysis.2022Pharmaceutics
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular. dermatological, enthesitis and dactylitis outcomes.2022Rheumatic & Muscoskeletal Diseases
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.2022Journal of Dermatological Treatment
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. 2022The Cochrane Database of Systematic Reviews
Biologics for pediatric psoriasis: a systematic review and meta-analysis.2022Pediatric dermatology
Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis.2022Dermatology and therapy
Towards personalized medicine in psoriasis: current progress.2022Psoriasis
Comparative efficacy and safety of Janus Kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: a systematic review and meta-analysis.2022Pharmacology
Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis.2022Frontiers in medicine
Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis.2022Advances in therapy
Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis.2022Inflammopharmacology
Evidence for the use of secukinumab in patients with radiographic and non-radiographic axial spondyloarthritis in the last 5 years.2022Rheumatology and therapy
Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis.2022Chinese medical journal
Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials.2022Seminars in arthritis and rheumatism.
Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey: a multicenter retrospective study and systematic review of the literature.2022Asian Pacific Journal of Allergy and Immunology
Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis.2021Dermatology and Therapy
Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis.2021European Review for Medical and Pharmacological Sciences
Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: a combined and updated meta-analysis.2021Journal of Clinical Pharmacy and Therapeutics
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis.2021Dermatologic Therapy
Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: a network meta-analysis. 2021International Journal of Clinical Pharmacology and Therapeutics
Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors.2021International Journal of Clinical Pharmacology and Therapeutics
A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains.2021Frontiers in Medicine
Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review.2021Dermatology and Therapy
Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials.2021Clinical Rheumatology
Efficacy and safety of anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a meta-analysis.2021Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
A pooled analysis reporting the efficacy and safety of secukinumab in male and female patients with ankylosing spondylitis.2021Rheumatology and therapy
Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies.2021Rheumatology and therapy
Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal phase III studies.2021The Journal of rheumatology
Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis.2021International journal of clinical pharmacology and therapeutics
Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis.2021Zeitschrift fur Rheumatologie
Short-term efficacy and safety of secukinumab for ankylosing spondylitis: a systematic review and meta-analysis of RCTs.2020Mediators of Inflammation
Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence.2020BioDrugs
Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review.2020JAMA Dermatology
The effects of selected biologics and a small molecule on health-related quality of Life in adult plaque psoriasis patients: a systematic review and meta-analysis.2020PLoS One
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis2020The British journal of dermatology
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.2020Annals of the Rheumatic Diseases
Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis.2020The Journal of Rheumatology
Fourteen small molecule and biological agents for psoriatic arthritis: a network meta-analysis of randomized controlled trials.2020Medicine
Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis.2020Arthritis Research & Therapy
Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes.2020Clinical and Experimental Rheumatology
Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network meta-analyses.2020Dermatology and Therapy
Short-term efficacy and safety of il-17, il-12/23, and il-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials.2019Journal of Immunology Research
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.2019Arthritis Research & Therapy
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.2019Arthritis Research & Therapy
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019PloS One
A cost-per-number needed to treat analysis assessing the efficiency of biologic drugs in moderate to severe plaque psoriasis.2019Actas Dermo-sifiliograficas

Clinical Practice Guidelines

Document TitleYearSource
Practical update of the guidelines published by the psoriasis group of the Spanish academy of dermatology and venereology (GPs) on the treatment of psoriasis with biologic agents: part 2----management of special populations, patients with comorbid conditions, and risk [translated article].2022Actas Dermo-Sifiliográficas
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.2022Nature Reviews Rheumatology
Indonesian clinical practice guidelines for systemic and biologic agents for adults with plaque psoriasis.2021Journal of General - Procedural Dermatology & Venereology Indonesia
2021 clinical practice guideline for the early detection, diagnosis, treatment, and monitoring of patients with axial spondyloarthritis. Colombian Association of Rheumatology.2021Reumatologia Clinica
Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper.2020Journal of Cutaneous Medicine and Surgery
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.2020British Journal of Dermatology
EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – Part 1: treatment and monitoring recommendations.2020Journal of the European Academy of Dermatology and Venereology
2019 Update of the American College of Rheumatology/Spondylitis association of America/Spondyloarthritis Research and Treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis.2019Arthritis & Rheumatology
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.2019Journal of the American Academy of Dermatology